- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04224974
Emotie- en symptoomgerichte betrokkenheidsproef voor personen met acute leukemie (EASE)
Emotion and Symptom-Focused Engagement (EASE): een multi-site gerandomiseerde gecontroleerde studie van een interventie voor personen met acute leukemie
The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early palliative care for symptom control, reduces psychological distress and physical symptom burden in individuals newly diagnosed with acute leukemia. To do this, half of the participants in this study will receive the usual care offered to patients with acute leukemia and half of the participants will receive usual care plus the EASE intervention.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The standard or usual care treatment for patients with newly diagnosed acute leukemia involves admission to hospital for treatment (e.g. induction chemotherapy). Additional support services may be delivered if requested or if a doctor thinks it is necessary.
Little research has been done looking at the psychological and physical consequences of being diagnosed with and treated for acute leukemia, but our research team has found that a significant number of these individuals experience symptoms of traumatic stress and severe physical symptoms. Even less research has been done looking at ways to help alleviate this psychological and physical distress. Emotion and Symptom-focused Engagement (EASE) is an integrated psychosocial and early palliative care (symptom control) intervention designed to reduce psychological distress and physical symptom burden in patients newly diagnosed with acute leukemia. The EASE intervention provides i) tailored supportive psychotherapy (called EASE-psy) during the initial weeks of treatment to reduce symptoms of traumatic stress, and ii) symptom screening during the initial inpatient treatment period with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms (called EASE-phys).
A phase II trial of EASE in patients with newly diagnosed acute leukemia demonstrated feasibility and preliminary evidence that it reduces psychological distress and physical symptom severity compared to usual care. This new trial is a definitive phase III, multi-site randomized controlled trial to test the effectiveness of EASE at reducing psychological distress and physical burden.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Harriet Richardson
- Telefoonnummer: 613-533-6430
- E-mail: hrichardson@ctg.queensu.ca
Studie Contact Back-up
- Naam: Lois Shepherd
- Telefoonnummer: 613-533-6430
- E-mail: lshepherd@ctg.queensu.ca
Studie Locaties
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L 4L2
- Werving
- Regional Health Authority B, Zone 2
-
Contact:
- Alfonso Rivera Duarte
- Telefoonnummer: 506 648-7109
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Werving
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Contact:
- Alejandro Garcia-Horton
-
Kingston, Ontario, Canada, K7L 2V7
- Werving
- Kingston Health Sciences Centre
-
Contact:
- Annette Hay
- Telefoonnummer: 77094 613 533-6430
-
Ottawa, Ontario, Canada, K1H 8L6
- Werving
- Ottawa Hospital Research Institute
-
Contact:
- Pierre Villeneuve
- Telefoonnummer: 613
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- University Health Network
-
Contact:
- Gary Rodin
- Telefoonnummer: 416 946-4504
-
Toronto, Ontario, Canada, M4N 3M5
- Werving
- Odette Cancer Centre
-
Contact:
- Lee Mozessohn
- Telefoonnummer: 5847 416 480-5000
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Newly diagnosed AL (acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) chronic myelogenous leukemia (CML) in blast crisis; T-cell leukemia lymphoma (TLL), and AL of ambiguous lineage) and is recruited up to 1 week prior to hospital admission or within 2 weeks of hospital admission. For patients diagnosed with a mixed phenotype AL, the dominant sub-type must be identified for stratification purposes.
- Receiving or expected to receive induction therapy with curative intent at the time of recruitment.
- Age ≥ 18 years.
- Ability to pass the cognitive screening test at the time of recruitment (Short Orientation-Memory-Concentration Test (SOMC) score ≥ 20), unless deemed suitable at the CRA's discretion (e.g. in extenuating circumstances such as interruptions during the administration of the measure or when patients report a learning disability that can influence the results).
- Patient is fluent in English and is able (i.e. sufficiently literate and competent) and willing to complete the baseline questionnaires in English. Ability but unwillingness to complete the baseline questionnaires will make the patient ineligible.
Exclusion Criteria:
- Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or inability to speak).
- Receiving on-site (in hospital) psychological/psychiatric counseling at the time of recruitment.
- Receiving on-site (in hospital) palliative care services at the time of recruitment.
- A diagnosis of acute promyelocytic leukemia.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Overig: gebruikelijke zorg
|
The usual care group will receive usual care of their acute leukemia at their centre but no formal psychological or palliative care intervention as part of this trial |
|
Experimenteel: Behavioral: Usual Care + EASE Intervention-psy
EASE Intervention = EASE-psy + EASE-phys |
All patients randomized to EASE will receive tailored supportive psychotherapy over the initial 8 weeks following the diagnosis of acute leukemia. The psychotherapy will be delivered by trained therapists and combines elements of relational support, affect regulation, and trauma-informed cognitive behavioural therapy (CBT). -EASE-phys: All patients randomized to EASE will receive weekly symptom screening during the initial inpatient treatment period (typically 4 weeks) with triggered referral to early palliative care (symptom control) to help manage moderate to severe physical symptoms based on a philosophy of multidisciplinary care and comprehensive assessment of symptoms. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Assess the effect of the EASE intervention compared to usual care to reduce traumatic stress symptoms using the Stanford Acute Stress Reaction questionnaire (SASRQ)
Tijdsspanne: 4 weeks
|
This 30-item measure assesses severity of traumatic stress symptoms over the past four weeks; it has been updated to be Diagnostic and Statistical Manual of Mental Disorders (DSM-5)-concordant [American Psychiatric Association 2013] for acute stress disorder (ASD). Mean severity of traumatic stress symptoms at 4 weeks will be the first primary outcome |
4 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Beoordeel het effect van de EASE-interventie in vergelijking met gebruikelijke zorg om traumatische stresssymptomen te verminderen met behulp van de SASRQ
Tijdsspanne: 8 weken, 12 weken & 26 weken
|
8 weken, 12 weken & 26 weken
|
|
|
Beoordeel het effect van de EASE-interventie op de gebruikelijke zorg om de ernst van de lichamelijke symptomen te verminderen met behulp van de MSAS
Tijdsspanne: 8 weken, 12 weken & 26 weken
|
8 weken, 12 weken & 26 weken
|
|
|
Beoordeel het effect van de EASE-interventie in vergelijking met gebruikelijke zorg op het aantal deelnemers dat voldoet aan criteria die consistent zijn met een diagnose van ASS en drempel-ASS op basis van DSM-5-criteria met behulp van de SASRQ
Tijdsspanne: 4, 8, 12 en 26 weken
|
4, 8, 12 en 26 weken
|
|
|
Beoordeel het effect van de EASE-interventie in vergelijking met de gebruikelijke zorg op het aantal fysieke symptomen van kanker en de bijbehorende symptoomgerelateerde stress zoals gemeten door de (MSAS)
Tijdsspanne: 4, 8, 12 & 26 weken
|
4, 8, 12 & 26 weken
|
|
|
Beoordeel het effect van de EASE-interventie in vergelijking met gebruikelijke zorg op de tevredenheid van de patiënt over de zorg met behulp van de 16-item FAMCAR-P16
Tijdsspanne: 4, 8, 12 en 26 weken
|
4, 8, 12 en 26 weken
|
|
|
10) De EQ-5D-5L zal worden gebruikt om de algemene gezondheidsstatus te meten, zodat deze kan worden gebruikt om voor kwaliteit gecorrigeerde levensjaren (QALY) te berekenen in een economische evaluatie die de baten en kosten van de EASE-interventie vergelijkt
Tijdsspanne: 4, 8, 12, 26 en 52 weken
|
4, 8, 12, 26 en 52 weken
|
|
|
Om progressievrije overleving tussen behandelingsarmen te vergelijken
Tijdsspanne: 1 jaar
|
1 jaar
|
|
|
Assess the effect of the EASE intervention compared to usual care to reduce physical symptom severity using the Memorial Symptom Assessment Scale (MSAS)
Tijdsspanne: 4 weeks
|
This reliable and valid instrument assesses symptom prevalence, severity and distress associated with 26 common physical and 6 psychological symptoms of cancer. Mean physical symptom severity at 4 weeks will be the second primary outcome |
4 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on Quality of Life using The Functional Assessment of chronic Illness Therapy-Spiritual Well-being Scale
Tijdsspanne: 4, 8, 12, 26 and 52 weeks
|
Individual subscales of the FACIT-Sp provide scores for physical, social/family, emotional, functional spiritual well-being |
4, 8, 12, 26 and 52 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on depressive symptoms using The Patient Health Questionnaire-9 (PHQ-9)
Tijdsspanne: 4, 8 ,12 and 26 weeks
|
This valid 9-item measure of depression has been widely used with patients with advanced cancer. Two additional items assessing intent to cause self-harm and interference with daily activities were included in the measure to ensure patients' safety but are not considered for data analysis. |
4, 8 ,12 and 26 weeks
|
|
Assess the effect of the EASE intervention compared to usual care on pain using the modified Brief Pain Inventory-Sort Form (BPI)
Tijdsspanne: 4, 8 12 and 26 weeks
|
The BPI is a widely used measure to rapidly assess the severity of pain and its impact on functioning and will be assessed as part of the secondary outcomes |
4, 8 12 and 26 weeks
|
|
The modified brief Experiences in Close Relationships Scale (ECR-M16) is an instrument to measure attachment security or the ability to rely on close others for support when distressed.
Tijdsspanne: Baseline
|
It provides subscale scores assessing attachment anxiety (i.e. fear of abandonment) and attachment avoidance (i.e. defensive independence). The ECR-M16 will only be administered at baseline in both arms of the study. |
Baseline
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie stoel: Gary Rodin, Princess Margaret Hospital, Canada
- Studie stoel: Camilla Zimmerman, Princess Margaret Hospital, Canada
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- SC26
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .